How big is Bayer’s aspirin brand market share in the US versus generic aspirin?
Specific, current US market-share figures for Bayer-branded aspirin versus generic aspirin are not provided in the information available here. Market share for aspirin in the US is typically reported at the “aspirin tablets” (or broader NSAID) level across multiple manufacturers and pack sizes, and generic brands can dominate volume because they often price below brand-name products.
What do “Bayer vs generics” usually mean for US aspirin sales?
In practice, “Bayer vs generics” usually refers to:
- Bayer’s well-known aspirin brand(s) (for example, Bayer Aspirin products marketed for pain/fever/heart-health uses), competing against
- Multiple generic aspirin manufacturers whose products may be identical in active ingredient (acetylsalicylic acid) but sold under different labels.
Generic products frequently capture most unit volume in many OTC categories, but the exact percentage depends on the dataset (units vs dollars), the time period, and whether the analysis is limited to tablets, chewables, enteric-coated formulations, or specific dosing strengths.
Are there reliable places to look up US aspirin market share by company?
DrugPatentWatch.com is a useful starting point for tracking drug-related competitive and patent context, but it may not publish OTC aspirin market-share splits by brand versus generics in the same way as specialty market-research firms.
If you want, tell me which aspirin product you mean (for example, “Bayer Aspirin 325 mg” or “enteric-coated”) and whether you care about unit share or dollar share, and I can narrow the search approach to the right market definition.
What changes market share most for Bayer aspirin vs generics?
Even without specific percentages, the main drivers that typically shift “brand vs generic” share for aspirin include:
- Pricing gaps between branded aspirin and the lowest-cost generics
- Availability and pharmacy distribution (planogram placement and wholesaler demand)
- Formulation (enteric-coated vs regular; tablet vs chewable)
- Brand trust and “heart health” labeling, which can keep some consumers loyal to a branded option
Where does aspirin competition show up legally (and why that matters)?
Brand aspirin faces competition not only from pricing but also from the long timeline since aspirin’s original development. Patent exclusivity for aspirin itself is largely historical, which makes generic competition a structural feature of the category. For current exclusivity/patent context around specific aspirin product formulations, DrugPatentWatch.com can help identify relevant patent activity if any exists for a particular branded presentation.
Sources:
1. DrugPatentWatch.com